Vivitrol Treatment: Monthly Injection for Opioid and Alcohol Recovery

Vivitrol is the brand name for extended-release naltrexone, an FDA-approved monthly injection used to treat both opioid use disorder and alcohol use disorder. Approved for alcohol dependence in 2006 and opioid dependence in 2010, Vivitrol takes a fundamentally different path than other medication-assisted treatment options: it's an opioid antagonist, meaning it blocks opioid receptors rather than activating them. That makes Vivitrol the only FDA-approved injectable MAT medication with zero abuse potential.

How Vivitrol Works

Vivitrol For Opioids Vs Alcohol

Vivitrol treatment follows a structured process — starting with preparation and assessment, moving through the injection itself, and continuing with ongoing monthly visits. Knowing each phase ahead of time helps patients know what to expect and improves the odds of a smooth start and steady long-term adherence.

Before Starting Vivitrol

The Injection Process

Ongoing Treatment

Starting Vivitrol means meeting a few specific clinical requirements, aimed at keeping patients safe and treatment effective. These requirements differ depending on whether Vivitrol is being used for opioid or alcohol use disorder. Knowing them ahead of time helps patients prepare and avoid complications — especially the risk of precipitated withdrawal for anyone dependent on opioids.

For opioid use disorder: Patients need to be completely free of all opioids — including heroin, fentanyl, prescription painkillers, methadone, and buprenorphine — for a minimum of 7 to 14 days before the first injection. This gets verified through urine drug screening, clinical assessment, and often a naloxone challenge test. Completing medical detox under supervised care is the safest way to meet this requirement. Patients transitioning off methadone need an even longer abstinence window because of methadone's long half-life — typically 14 days or more.

For alcohol use disorder: Patients don't need to be abstinent from alcohol before starting Vivitrol, though they shouldn't be in active alcohol withdrawal (which should be managed medically on its own). A genuine commitment to abstinence as a goal still matters, since Vivitrol eases cravings and reward but doesn't block the physical effects of alcohol itself. Anyone drinking heavily should talk with their provider about a safe plan for cutting back or stopping.

General medical requirements for all patients include adequate liver function (confirmed by blood work), no acute hepatitis, no known hypersensitivity to naltrexone or the injection components, and no current need for opioid pain medications. Patients should share a full medication history, since several drug interactions can affect Vivitrol safety. Anyone pregnant or planning to become pregnant should discuss the risks with their provider — naltrexone is classified as FDA Pregnancy Category C, meaning animal studies show some adverse effects but human data remains limited.

Vivitrol offers a distinct set of advantages that make it an appealing option for many people recovering from opioid or alcohol addiction. Its non-opioid mechanism, monthly schedule, and zero abuse potential set it apart from other MAT medications and remove several common barriers to sticking with treatment.

• Zero abuse potential — As an opioid antagonist, Vivitrol can't be misused for euphoric effects, which removes concerns about diversion or dependence on the medication itself
• Monthly dosing removes daily decisions — One injection a month lifts the burden of daily adherence, one of the leading reasons oral medications fall through
• No physical dependence — Patients don't develop tolerance or withdrawal symptoms from Vivitrol, which makes stopping straightforward when it's clinically appropriate
• Treats both opioid and alcohol use disorders — Vivitrol is the only injectable MAT medication FDA-approved for both, useful for patients managing co-occurring opioid and alcohol disorders
• No DEA scheduling restrictions — Unlike methadone (Schedule II) and buprenorphine (Schedule III), naltrexone isn't a controlled substance, which simplifies prescribing
• Office-based administration — Any licensed provider in any healthcare setting can give Vivitrol, unlike methadone, which requires specialized clinic certification
• Fits abstinence-based recovery values — Because Vivitrol isn't an opioid itself, patients and recovery communities that prefer a non-opioid approach often find it a more comfortable fit

The landmark COMBINE study for alcohol use disorder and the X:BOT trial for opioid use disorder both back up Vivitrol's clinical effectiveness. For patients able to complete the detox period opioid treatment requires, Vivitrol delivers outcomes comparable to other MAT medications while offering the distinct advantages of a non-opioid mechanism and monthly convenience.

Vivitrol is generally well-tolerated, though it's worth knowing about both common and rare side effects. Most reported side effects relate to the injection site or the body's adjustment to opioid receptor blockade. As with any medication, weigh the benefits against potential side effects, and let your provider know promptly about anything concerning.

Common side effects include injection site reactions (pain, hardness, lumps, or redness), nausea, headache, fatigue, dizziness, and reduced appetite. Injection site reactions are the most common, showing up in roughly 70% of patients in clinical trials, though most are mild and clear up within one to two weeks. Nausea tends to be more noticeable after the first injection and eases with later doses. These common effects are manageable and rarely require stopping treatment.

Serious side effects are rare but worth knowing. The FDA label carries warnings about hepatotoxicity (liver damage), so liver function should be checked periodically during treatment. Injection site reactions can occasionally progress to induration, cellulitis, or, very rarely, tissue damage requiring surgery — contact your provider if you notice increasing pain, swelling, or skin darkening at the site. Depression and suicidal thoughts have been reported in some patients on naltrexone, though a direct cause-and-effect link hasn't been firmly established.

One important safety note: because Vivitrol blocks opioid receptors, opioid-based pain medications won't work while it's active. Patients should carry a medical alert card or wear a medical alert bracelet noting they're on naltrexone, so emergency personnel can use non-opioid pain management if needed. Trying to override the blockade with large doses of opioids is extremely dangerous and can lead to fatal overdose once the naltrexone wears off, or through other pathways entirely.

Choosing between Vivitrol, buprenorphine-based options , and methadone-based programs is one of the more consequential decisions in opioid addiction care. Each medication has its own mechanism, advantages, and limitations, and the right fit depends heavily on individual circumstances. Ideally, this is a decision made together with a treatment provider after a thorough clinical assessment.

Vivitrol (naltrexone) is the only non-opioid option of the three. As an antagonist, it blocks opioid effects entirely rather than activating receptors to any degree. The monthly injection removes daily adherence worries, and it carries zero potential for physical dependence or misuse. That said, the 7-to-14-day opioid abstinence requirement before starting is a real barrier — the X:BOT trial found noticeably fewer patients were able to successfully start Vivitrol compared to buprenorphine. Vivitrol also doesn't treat withdrawal symptoms or offer any opioid-receptor-mediated craving relief.

Buprenorphine (Suboxone, Subutex, Sublocade) is a partial opioid agonist that can be prescribed in office settings and taken at home. It can start during mild withdrawal without an extended detox, has a ceiling effect that limits overdose risk, and comes in several forms, including sublingual film and a monthly injection (Sublocade). It's the most widely prescribed MAT medication and offers the most prescribing flexibility. Its downsides include some potential for misuse (though lower than full agonists) and, with the sublingual form, the need for daily self-administration.

Methadone is a full opioid agonist with the longest track record and potentially the strongest efficacy for severe opioid dependence. It can start right away with no withdrawal requirement and works well for people dependent on high-potency opioids like fentanyl. However, it requires daily clinic visits at the start, carries the highest respiratory depression risk of the three, and has some potential for misuse and diversion. The right choice among these three should come down to whichever option is most likely to keep an individual patient engaged in treatment.

Vivitrol is a flexible option that can help a wide range of people recovering from opioid or alcohol addiction. But its distinct traits — the detox requirement for opioids, the non-opioid mechanism, and monthly dosing — make it a particularly good fit for certain patients. Matching the right medication to the right person is a big part of what makes MAT succeed.

Patients who've completed medical detox and reached initial opioid abstinence tend to be strong candidates for Vivitrol. This includes people transitioning out of residential treatment programs, where the detox period is already built into the schedule. People who prefer a non-opioid approach — whether from personal philosophy, concerns about medication dependence, or past experiences with agonist therapies — often find Vivitrol lines up with their recovery values. People navigating the criminal justice system, including those in drug courts or on probation, frequently benefit from Vivitrol's zero abuse potential and easily verified monthly dosing.

For alcohol use disorder, Vivitrol suits people at any stage of recovery who want medication support for staying abstinent. It's especially useful for anyone who struggles with daily medication adherence, since the monthly shot removes the need for a daily pill. Healthcare workers, pilots, and others in safety-sensitive jobs who need a non-opioid option often choose Vivitrol too. Younger adults early in their recovery journey can also be good candidates, since Vivitrol avoids introducing any opioid receptor activation for people whose physical dependence may be less severe.

Vivitrol can fit into nearly any level of addiction treatment, from residential programs to outpatient care. Its monthly schedule and lack of abuse potential make it one of the more flexible MAT medications when it comes to matching a care setting. Knowing how it fits at each level helps patients and providers plan a cohesive, long-term strategy.

In residential treatment settings, Vivitrol is often started during the final phase of the program. The supervised, structured environment is ideal for completing the opioid detox required beforehand. Patients can receive their first dose before discharge, so they leave with active medication protection during the vulnerable transition back to daily life — an approach shown to meaningfully improve post-discharge outcomes in several studies.

At the intensive outpatient (IOP) level, Vivitrol complements a structured therapy schedule with reliable medication coverage between sessions. Patients attend IOP programming several days a week while keeping up with their monthly injection, combining pharmacological and psychosocial support in one plan. Because the time commitment is so minimal, Vivitrol doesn't compete with therapy scheduling the way daily-visit medications can.

In standard outpatient and primary care settings, Vivitrol works as a maintenance medication for people who've moved through more intensive levels of care. The monthly visit for the injection becomes a built-in touchpoint with the healthcare system, even for patients who've stepped down from structured programming. Any licensed provider can give Vivitrol — no special certification, DEA waiver, or clinic accreditation required — so patients can get their injections from a primary care physician, psychiatrist, or addiction specialist, whichever is most convenient.